Where Will Recursion Pharmaceuticals Be in 5 Years?

If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...
ZDNet

The great puzzle of the body and disease is beginning to yield to AI, says Recursion CEO

One way to think about artificial intelligence, in its modern deep learning form, is as a jigsaw puzzle. You have a picture on the box, and you begin to organize your pieces. "I usually start by ...
KTLA

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...
Benzinga.com

Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On?

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower in Wednesday’s after-hours session after the company announced a proposed offering of its common stock. What Happened: After the ...